Neurology:缺血性卒中后30天到90天内早期随访与再入院之间关系

2020-02-21 xing.T MedSci原创

由此可见,早期门诊保健科随访与减少30天的住院率有关。急性卒中入院后,早期门诊随访可能是进行干预的重要机会。

近日,神经病学领域权威取杂志Neurology上发表了一篇研究文章,该研究旨在评估急性缺血性卒中后30天内和90天内保健科或神经内科早期随访是否与较低的全因再入院率相关。

研究人员使用对2009年至2015年美国受保人的全国代表性数据库PharMetrics进行了一项回顾性队列研究,对急性缺血性卒中后出院的患者进行了ICD-9和ICD-10代码识别。该研究的主要预测指标是患者出院后30到90天内进行门诊保健科或神经科随访,主要结局是30天内和90天内再次入院。研究人员使用多变量Cox模型,将保健科和神经科就诊指定为时间依赖性协变量,并调整患者的人口统计学指标、合并症和卒中严重程度。

该队列纳入了14630名患者。7.3%的患者在30天内再次入院,而13.7%的患者在90天内再次入院。到30天时,有59.3%的人到保健科就诊,而24.4%的人到神经科就诊。保健科随访与30天再入院率降低相关(风险比[HR]为0.84,95%置信区间[CI]为0.72–0.98)。90天之前的保健科随访未达到显著水平(HR为0.92,95%CI为0.83–1.03)。神经科随访与30或90天内的再入院率降低之间没有关联(分别为HR为1.05;HR为1.00)。

由此可见,早期门诊保健科随访与减少30天的住院率有关。急性卒中入院后,早期门诊随访可能是进行干预的重要机会。

原始出处:

Michelle H. Leppert,et al.Relationship between early follow-up and readmission within 30 and 90 days after ischemic stroke.Neurology.2020.https://n.neurology.org/content/early/recent

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000984, encodeId=0297200098435, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Mar 07 15:32:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977828, encodeId=028e19e7828af, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 23 05:32:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893265, encodeId=303f1893265ef, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Jul 10 05:32:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671397, encodeId=1d9016e139715, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Oct 02 13:32:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806377, encodeId=b3cf18063e7de, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Feb 03 20:32:00 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379482, encodeId=d9ce3e9482f7, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Feb 21 13:39:54 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026564, encodeId=0599102656409, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Feb 21 13:32:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-03-07 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000984, encodeId=0297200098435, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Mar 07 15:32:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977828, encodeId=028e19e7828af, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 23 05:32:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893265, encodeId=303f1893265ef, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Jul 10 05:32:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671397, encodeId=1d9016e139715, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Oct 02 13:32:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806377, encodeId=b3cf18063e7de, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Feb 03 20:32:00 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379482, encodeId=d9ce3e9482f7, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Feb 21 13:39:54 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026564, encodeId=0599102656409, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Feb 21 13:32:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-02-23 smlt2008
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000984, encodeId=0297200098435, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Mar 07 15:32:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977828, encodeId=028e19e7828af, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 23 05:32:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893265, encodeId=303f1893265ef, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Jul 10 05:32:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671397, encodeId=1d9016e139715, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Oct 02 13:32:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806377, encodeId=b3cf18063e7de, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Feb 03 20:32:00 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379482, encodeId=d9ce3e9482f7, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Feb 21 13:39:54 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026564, encodeId=0599102656409, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Feb 21 13:32:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2000984, encodeId=0297200098435, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Mar 07 15:32:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977828, encodeId=028e19e7828af, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 23 05:32:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893265, encodeId=303f1893265ef, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Jul 10 05:32:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671397, encodeId=1d9016e139715, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Oct 02 13:32:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806377, encodeId=b3cf18063e7de, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Feb 03 20:32:00 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379482, encodeId=d9ce3e9482f7, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Feb 21 13:39:54 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026564, encodeId=0599102656409, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Feb 21 13:32:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2000984, encodeId=0297200098435, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Mar 07 15:32:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977828, encodeId=028e19e7828af, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 23 05:32:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893265, encodeId=303f1893265ef, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Jul 10 05:32:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671397, encodeId=1d9016e139715, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Oct 02 13:32:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806377, encodeId=b3cf18063e7de, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Feb 03 20:32:00 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379482, encodeId=d9ce3e9482f7, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Feb 21 13:39:54 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026564, encodeId=0599102656409, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Feb 21 13:32:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2000984, encodeId=0297200098435, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Mar 07 15:32:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977828, encodeId=028e19e7828af, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 23 05:32:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893265, encodeId=303f1893265ef, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Jul 10 05:32:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671397, encodeId=1d9016e139715, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Oct 02 13:32:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806377, encodeId=b3cf18063e7de, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Feb 03 20:32:00 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379482, encodeId=d9ce3e9482f7, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Feb 21 13:39:54 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026564, encodeId=0599102656409, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Feb 21 13:32:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-02-21 qingfengqishi5

    学习了,学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2000984, encodeId=0297200098435, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Mar 07 15:32:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977828, encodeId=028e19e7828af, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 23 05:32:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893265, encodeId=303f1893265ef, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Jul 10 05:32:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671397, encodeId=1d9016e139715, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Oct 02 13:32:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806377, encodeId=b3cf18063e7de, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Feb 03 20:32:00 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379482, encodeId=d9ce3e9482f7, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Feb 21 13:39:54 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026564, encodeId=0599102656409, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Feb 21 13:32:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-02-21 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

相关资讯

Stroke:循环中性激素结合球蛋白与缺血性卒中风险

在这个绝经后妇女的前瞻性队列中,血清SHBG水平与IS风险之间存在显著的负相关,这些结果支持SHBG可以用作预测妇女IS危险分层工具的观点。

Stroke:绝经后妇女血浆雌二醇和睾丸激素水平与缺血性卒中的关系

由此可见,该研究的结果不支持性激素介导了绝经后妇女缺血性卒中风险的作用。需要在其他更大型的研究中进行重复验证。

Neurology:血清维生素B12和叶酸与MTHFR基因型相互作用对缺血性卒中风险的影响

由此可见,在叶酸和B12含量均低的高血压患者中,首次缺血性卒中的风险明显更高。叶酸治疗对低叶酸和B12的CC基因型个体以及高叶酸和B12的TT基因型个体效果最明显。

阿斯利康的Brilinta可改善轻度急性缺血性卒中或短暂性脑缺血发作后的预后

阿斯利康周一报道,III期研究的主要结果显示,与单独使用阿司匹林相比,与阿司匹林联合Brilinta(替卡格雷)可显著降低急性缺血性卒中或短暂性脑缺血发作后中风和死亡的风险。

NEJM:缺血性卒中后低密度脂蛋白胆固醇两种降脂目标的比较

短暂性脑缺血发作(TIA)和动脉粥样硬化缺血性卒中后,推荐使用他汀类药物强化降脂治疗。然而,减少卒中后心血管事件发生率的低密度脂蛋白(LDL)胆固醇的降脂水平尚未得到深入研究。

Neurology:阿尔茨海默病患者出血性和缺血性卒中风险

由此可见,与具有相似风险特征的非AD对照相比,AD患者出血性卒中而非缺血性卒中的风险更高。